Hypofibrinogenemia is a rare disorder, which is characterized by a decrease in fibrinogen levels (&lt;1.5 g/L), normal plasma fibrinogen levels that range from 1.5 g/L to 4.5 g/L. It is classified into two types, that is, Congenital Hypofibrinogenemia and Acquired Hypofibrinogenemia.
&nbsp;
Fibrinogen is the main protein for clot formation that provides a matrix and mesh network required for clot strength. Maintaining fibrinogen levels is a vital therapeutic target in bleeding patients, especially in perioperative settings. Low fibrinogen levels are associated with decreased clot strength and are strongly associated with severe bleeding.&nbsp;
&nbsp;
Congenital fibrinogen disorders are caused due to genetic variants occurring within all three fibrinogen genes. But, each gene (FGA, FGB, FGG) differently displays specific variants, wherein &ldquo;nonsense&rdquo; variants are mostly found within FGA, while FGG variants are prevalently responsible for missense changes.&nbsp;
&nbsp;
In congenital Hypofibrinogenemia, genes responsible for producing fibrinogen (a critical blood clotting factor) cannot make a functional fibrinogen glycoprotein due to an inherited mutation. In contrast, acquired Hypofibrinogenemia can result from either severe hepatic disease or disseminated intravascular coagulation (DIC), cardiac surgery, etc.&nbsp;
&nbsp;
Hypofibrinogenemia Epidemiological Segmentation&nbsp;
The Epidemiological Segmentation of Hypofibrinogenemia in 7MM from 2017 to 2030 is segmented as:-&nbsp;
<ul>
<li>Total Cases&nbsp;</li>
<li>Type-Specific Cases&nbsp;</li>
<li>Acquired Hypofibrinogenemia cases</li>
</ul>
&nbsp;
Hypofibrinogenemia Epidemiology&nbsp;
<ul>
<li>The total prevalent population of Hypofibrinogenemia in 7MM in 2017 was 11,084&nbsp;&nbsp;</li>
<li>The prevalent population of Hypofibrinogenemia in Spain in 2017 was 493</li>
</ul>
&nbsp;
<a style="color: #0066cc; background-color: transparent;" href="https://www.delveinsight.com/report-store/hypofibrinogenemia-market" target="_blank" rel="noopener noreferrer">Hypofibrinogenemia Market</a>
The market size of Hypofibrinogenemia in 7MM in 2017 was USD 161.5 Million.
&nbsp;
Hypofibrinogenemia Emerging Drugs
The emerging drugs of the Hypofibrinogenemia market are&nbsp;
<ul>
<li>BT524</li>
</ul>
And many others.&nbsp;&nbsp;
&nbsp;
Hypofibrinogenemia Marketed therapies
The Marketed therapies of the Hypofibrinogenemia market are&nbsp;
<ul>
<li>RiaSTAP</li>
<li>Fibryna</li>
<li>FibCLOT (Clottafact)</li>
</ul>
And many others.&nbsp;&nbsp;
&nbsp;
Hypofibrinogenemia Key Players
The key players in the Hypofibrinogenemia market are
<ul>
<li>Biotest&nbsp;</li>
<li>CSL Behring</li>
<li>Octapharma</li>
<li>LFB Biomedicaments</li>
</ul>
And many others.&nbsp;

Hypofibrinogenemia Market

Hypofibrinogenemia Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.